argenex (NASDAQ:ARGX) Posts Earnings Results, Misses Estimates By $0.27 EPS

argenex (NASDAQ:ARGX) posted its earnings results on Thursday. The company reported $5.52 EPS for the quarter, missing analysts’ consensus estimates of $5.79 by ($0.27), FiscalAI reports. argenex had a return on equity of 33.28% and a net margin of 31.31%.The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.44 billion.

Here are the key takeaways from argenex’s conference call:

• argenx reported strong Q1 results with product net sales of $1.3 billion (63% YoY), an operating profit of $394 million, and a cash balance of $4.9 billion, supporting margin expansion and continued investment in growth.
• Commercial momentum for VYVGART remains strong — Q1 new patient starts were among the highest since launch, the medicine is the #1 prescribed biologic in gMG, the prefilled syringe materially increased demand, and a PDUFA for seronegative MG is imminent with ocular and pediatric expansions planned.
• The company is advancing its second product, empasiprubart, toward a pivotal readout expected in 4Q and argues C2-targeting could offer clinical advantages across CIDP/MMN and other complement-driven indications, positioning a second launch to deepen neuromuscular leadership.
• argenx is broadening its pipeline and sourcing strategy — five clinical-stage molecules (including phase III–ready ARGX‑213 and an oral FcRn collaboration), a China entity, and targeted strategic investments to sustain long-term growth and indication expansion.
• Near-term headwinds and risks include seasonal Q1 QoQ softness, rising competition (C5 inhibitors, other newcomers and potential head‑to‑head trials) largely in refractory settings, payer barriers to earlier-line adoption, and the need for disease awareness to access underdiagnosed populations like IMNM.

argenex Price Performance

Shares of NASDAQ:ARGX traded down $5.14 during midday trading on Friday, reaching $782.17. The company had a trading volume of 354,205 shares, compared to its average volume of 307,650. The stock’s fifty day moving average price is $755.88 and its 200-day moving average price is $817.54. The stock has a market capitalization of $48.64 billion, a P/E ratio of 35.05, a PEG ratio of 1.29 and a beta of 0.46. argenex has a one year low of $510.05 and a one year high of $934.62.

Institutional Trading of argenex

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its stake in shares of argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the last quarter. Morgan Stanley increased its stake in shares of argenex by 19.2% in the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after buying an additional 83,746 shares during the last quarter. Invesco Ltd. increased its stake in shares of argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares during the last quarter. Bank of America Corp DE increased its stake in shares of argenex by 1.9% in the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after buying an additional 6,259 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Guggenheim raised its price target on argenx to $1,135 and kept a buy rating, implying substantial upside from current levels. Guggenheim Raises ARGX Price Target
• Positive Sentiment: Wells Fargo also increased its price target to $1,260 and reiterated an overweight rating, signaling continued confidence in argenx’s long-term growth prospects. Wells Fargo Raises ARGX Price Target
• Neutral Sentiment: argenx reported Q1 2026 results and a business update, with investors parsing the details of the quarter and management’s outlook. argenx Q1 2026 Financial Results and Business Update
• Negative Sentiment: The company posted earnings of $5.52 per share, below the $5.79 consensus estimate, and revenue of $1.31 billion also missed expectations, which is likely weighing on the stock. Argenx Tops Earnings Expectations Despite Slight Revenue Shortfall

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARGX. Royal Bank Of Canada reduced their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Guggenheim boosted their target price on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,017.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.